Bronchiolitis Obliterans Syndrome Market
DelveInsight’s “Bronchiolitis Obliterans Syndrome (BOS) - Market Insights, Epidemiology, and Market Forecast - 2032” report delivers an in-depth understanding of the Bronchiolitis Obliterans Syndrome (BOS), historical and forecasted epidemiology as well as the Bronchiolitis Obliterans Syndrome (BOS) market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan.
The Bronchiolitis Obliterans Syndrome (BOS) market report provides current treatment practices, emerging drugs, Bronchiolitis Obliterans Syndrome (BOS) market share of the individual therapies, and current and forecasted Bronchiolitis Obliterans Syndrome (BOS) market size from 2019 to 2032 segmented by seven major markets. The report also covers current bronchiolitis obliterans syndrome treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assess the market’s underlying potential.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain), and the UK
- Japan
Study Period: 2019–2032
Bronchiolitis Obliterans Syndrome (BOS) Understanding and Treatment Algorithm
The DelveInsight’s bronchiolitis obliterans syndrome market report gives a thorough understanding of Bronchiolitis Obliterans Syndrome (BOS). It is an inflammatory condition affecting the lung’s tiniest airways. The bronchioles may become damaged and inflamed in affected people, leading to extensive scarring that blocks the airways. Many chemicals (such as nitrogen oxides, ammonia, welding fumes, or food flavoring fumes) and respiratory infections can cause lung injury, leading to Bronchiolitis Obliterans Syndrome (BOS). It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation.
Not everyone with Bronchiolitis Obliterans Syndrome (BOS) will have symptoms; the most common symptoms include shortness of breath, dry cough, and sometimes wheezing and fatigue in the absence of a cold or asthma. Symptoms will normally develop over a few weeks or months and flare up while exercising or manual labor. Depending on the exposure, other parts of the body may experience irritation. For example, a skin rash may develop in addition to respiratory problems. As the condition progresses, symptoms will worsen.
Bronchiolitis Obliterans Syndrome (BOS) may result from lung injury caused by various chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine, ammonia, oxides of nitrogen or sulfur dioxide, welding fumes, or food flavoring fumes (such as diacetyl). In addition, respiratory infections caused by a respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.
Continued in the report…
Diagnosis
Bronchiolitis Obliterans Syndrome (BOS) diagnosis is often suspected based on the presence of characteristic signs and symptoms. Additional testing can then be ordered to support and confirm the diagnosis. These tests may include imaging studies (such as a chest CT scan), pulmonary function tests, and surgical lung biopsy.
Continued in the report…
Treatment
Although there is no cure for Bronchiolitis Obliterans Syndrome (BOS), treatment may help stabilize or slow its progression. The best treatment options and the effectiveness of the selected treatments vary based on the underlying cause and the severity of the condition. Medications often prescribed to people with bronchiolitis obliterans include certain antibiotics (called macrolide antibiotics), corticosteroids, and immunosuppressive drugs.
The combination of budesonide/formoterol, montelukast, and n-acetylcysteine significantly improved lung function and respiratory symptoms in patients with Bronchiolitis Obliterans Syndrome (BOS) after allogeneic HSCT. Furthermore, combination therapy showed a better therapeutic response in patients with Bronchiolitis Obliterans Syndrome (BOS), who showed prominent lung function decreases between pre-HSCT and Bronchiolitis Obliterans Syndrome (BOS) diagnosis.
Continued in the report…
Bronchiolitis Obliterans Syndrome (BOS) Epidemiology
The Bronchiolitis Obliterans Syndrome (BOS) epidemiology division provides insights into the historical and current Bronchiolitis Obliterans Syndrome (BOS) patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed prevalent patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Bronchiolitis Obliterans Syndrome (BOS) epidemiology scenario in the 7MM covering the United States, EU4 and the UK, and Japan from 2019 to 2032.
- In 2022, the total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) were approximately 32,600 in the 7MM, which is expected to grow during the study period, i.e., 2019–2032.
- The disease epidemiology covered in the report provides historical as well as forecasted Bronchiolitis Obliterans Syndrome (BOS) epidemiology segmented as Total Diagnosed Prevalent Cases of Bronchiolitis Obliterans Syndrome (BOS), Grade-specific Cases of Bronchiolitis Obliterans Syndrome (BOS), Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM covering the United States, EU4 and the UK, and Japan from 2019 to 2032.
Country-wise Bronchiolitis Obliterans Syndrome (BOS) Epidemiology
The epidemiology segment also provides the Bronchiolitis Obliterans Syndrome (BOS) epidemiology data and findings across the United States, EU4 and the UK, and Japan.
- According to DelveInsight, in 2022, the total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) were approximately 17,000 in the United States, which is expected to grow during the study period, i.e., 2019–2032.
- The highest number of total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) was observed in Germany among EU4 and the UK, with approximately 3,900 cases in 2022 which are expected to grow during the study period, i.e., 2019–2032.
- In 2022, the total diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) were approximately 2,400 cases in Japan, which is expected to grow during the study period, i.e., 2019–2032.
Bronchiolitis Obliterans Syndrome (BOS) Drug Chapters
The drug chapter segment of the Bronchiolitis Obliterans Syndrome (BOS) report encloses a detailed analysis of Bronchiolitis Obliterans Syndrome (BOS) marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Bronchiolitis Obliterans Syndrome (BOS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Bronchiolitis Obliterans Syndrome (BOS) treatment.
Liposomal Cyclosporine A: Zambon Pharma
Liposomal Cyclosporine A for inhalation (L-CsA-i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L-CsA-i is administered via a drug-specific investigational eFlow technology nebulizer system. The investigational drug-device combination is designed to deliver L-CsA-i to the site of disease in the lung. L-CsA-i is currently being evaluated to treat Bronchiolitis Obliterans Syndrome (BOS) in patients aged 6 years and older in the BOSTON clinical development program, which comprises five ongoing or planned trials. The drug has been awarded Fast Track designation from the US FDA for the treatment of Bronchiolitis Obliterans Syndrome (BOS). As currently, no approved treatment is available for patients with Bronchiolitis Obliterans Syndrome (BOS), a rare, devastating disease that displays a huge unmet medical need. L-CsA-I can potentially address the existing unmet need of Bronchiolitis Obliterans Syndrome (BOS) and fetch maximum revenue.
Product details in the report…
MPH966 (alvelestat): Mereo Biopharma
MPH-966 (formerly AZD 9668) is a novel, oral-small molecule that inhibits neutrophil elastase (NE). This neutrophil protease is a key enzyme in destroying lung tissues. Alvelestat is currently being investigated in Phase I/II study in adult patients who have undergone hematopoietic stem cell transplantation and were diagnosed with Bronchiolitis Obliterans Syndrome (BOS). Interim results of Phase I/II clinical study of alvelestat have shown efficacious in the treatment of Bronchiolitis Obliterans Syndrome (BOS). Alvelestat is a disease-modifying agent and can be a blockbuster in treating Bronchiolitis Obliterans Syndrome (BOS).
Product details in the report…
Bronchiolitis Obliterans Syndrome (BOS) Market Outlook
Treatment of Bronchiolitis Obliterans Syndrome (BOS) after lung transplant/allo-HSCT involves augmenting immunosuppression as a form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone are used to treat Bronchiolitis Obliterans Syndrome (BOS) after transplant. Azithromycin has been demonstrated to improve lung function and lower the incidence of Bronchiolitis Obliterans Syndrome (BOS). The reduction in lung function in Bronchiolitis Obliterans Syndrome (BOS) post-HSCT can be slowed down by combining inhaled fluticasone, oral montelukast, and Zithromax. In addition to these treatments, reducing Bronchiolitis Obliterans Syndrome (BOS) is also advised by treating gastroesophageal reflux. Lung retransplantation may be necessary when Bronchiolitis Obliterans Syndrome (BOS) is progressive and severe. Extracorporeal photopheresis has also been successfully used to slow Bronchiolitis Obliterans Syndrome’s decline in lung function. In some clinics, off-label use of nintedanib and pirfenidone has recently demonstrated clinical efficacy and safety. However, further studies are required to validate these drugs as a new therapeutic option for patients with Bronchiolitis Obliterans Syndrome (BOS).
In non-transplant-related Bronchiolitis Obliterans Syndrome (BOS), removal from offending agents is essential. Immunosuppression with corticosteroids and cytotoxic agents like cyclophosphamide has been used for Bronchiolitis Obliterans Syndrome (BOS) related to rheumatoid arthritis but has not been beneficial for Bronchiolitis Obliterans Syndrome (BOS) from toxic inhalation or post-infectious etiology. If needed, symptomatic treatment should be provided with cough suppressants, inhaled bronchodilators, and oxygen supplementation in these patients.
Beyond azithromycin, no treatment is available for Bronchiolitis Obliterans Syndrome (BOS), and a successful course of treatment stabilizes or slows the rate of forced expiratory volume in one second (FEV1) drop. Optimizing immunosuppression to avoid additional lung allograft rejection is a key component of managing Bronchiolitis Obliterans Syndrome (BOS) patients. Although traditional immunosuppressive measures include repeated high-dose methylprednisolone and augmentation of immunosuppressive therapy with anti-thymocyte globulin, switching cyclosporine to tacrolimus is currently the most common initial treatment approach. Maintenance immunosuppression is typically a triple-drug regimen consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Other treatment strategies include inhaled cyclosporine, cell-cycle inhibitors, mammalian target of rapamycin inhibitors, and total lymphoid irradiation. Although each of these regimens effectively suppresses the immune system, most patients do not have a durable response. The clinical course is characterized by a progressive decline in lung function while exposing patients to all of the side effects of augmented immunosuppression.
Currently, there is no approved therapy in the 7MM to treat Bronchiolitis Obliterans Syndrome (BOS), and some potential therapeutic options are being investigated in the late stages of the disease and have the potential to change the market scenario of Bronchiolitis Obliterans Syndrome (BOS) in the coming years.
According to DelveInsight, the Bronchiolitis Obliterans Syndrome (BOS) market in 7MM is expected to witness a major change in 2019–2032.
Key Findings
The Bronchiolitis Obliterans Syndrome (BOS) market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Bronchiolitis Obliterans Syndrome (BOS) in the seven major markets is expected to increase during the study period (2019–2032). In 2022, the total market size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM was approximately USD 58 million, which is expected to rise during the study period (2019–2032).
The United States Market Outlook
The total market size of Bronchiolitis Obliterans Syndrome (BOS) in the United States accounted for approximately USD 31 million in 2022, which is expected to rise during the study period (2019–2032).
EU4 and the UK: Market Outlook
In EU4 and the UK, the total market size of Bronchiolitis Obliterans Syndrome (BOS) was approximately USD 24 million in 2022, which is expected to rise during the study period (2019–2032).
Japan Market Outlook
In Japan, the total market size of Bronchiolitis Obliterans Syndrome (BOS) was approximately USD 2 million in 2022, which is expected to rise during the study period (2019–2032).
Bronchiolitis Obliterans Syndrome (BOS) Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Bronchiolitis Obliterans Syndrome (BOS) market or expected to get launched in the market during the study period 2019–2032. The analysis covers Bronchiolitis Obliterans Syndrome (BOS) market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Bronchiolitis Obliterans Syndrome (BOS) Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Bronchiolitis Obliterans Syndrome (BOS) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers collaborations, acquisitions, mergers, licensing patent details, and other information for emerging Bronchiolitis Obliterans Syndrome (BOS) therapies.
Reimbursement Scenario in Bronchiolitis Obliterans Syndrome (BOS)
Approaching reimbursement can positively impact both during the late stages of product development and after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Bronchiolitis Obliterans Syndrome (BOS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Bronchiolitis Obliterans Syndrome (BOS) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Bronchiolitis Obliterans Syndrome (BOS) market by using various Competitive Intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Bronchiolitis Obliterans Syndrome (BOS), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
- Comprehensive insight has been provided into the Bronchiolitis Obliterans Syndrome (BOS) epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of the current and emerging therapies for Bronchiolitis Obliterans Syndrome (BOS) is provided, along with the assessment of new therapies that will impact the current treatment landscape.
- A detailed review of the Bronchiolitis Obliterans Syndrome (BOS) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Bronchiolitis Obliterans Syndrome (BOS) market.
Report Highlights
- In the coming years, the Bronchiolitis Obliterans Syndrome (BOS) market is set to change due to the upcoming therapies with a novel mechanism of actions that are under investigation and ongoing research in the Bronchiolitis Obliterans Syndrome (BOS), which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome (BOS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Bronchiolitis Obliterans Syndrome (BOS). Launching emerging therapies will significantly impact the Bronchiolitis Obliterans Syndrome (BOS) market.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bronchiolitis Obliterans Syndrome (BOS).
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Bronchiolitis Obliterans Syndrome (BOS) Report Insights
- Patient Population
- Therapeutic Approaches
- Bronchiolitis Obliterans Syndrome (BOS) Pipeline Analysis
- Bronchiolitis Obliterans Syndrome (BOS) Market Size and Trends
- Market Opportunities
- Impact of Upcoming Therapies
Bronchiolitis Obliterans Syndrome (BOS) Report Key Strengths
- 11 years Forecast
- 7MM Coverage
- Bronchiolitis Obliterans Syndrome (BOS) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Bronchiolitis Obliterans Syndrome (BOS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights
- What was the Bronchiolitis Obliterans Syndrome (BOS) drug class share (%) distribution in 2019, and how would it look in 2032?
- What would be the Bronchiolitis Obliterans Syndrome (BOS) total market size as well as market size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the key findings of the market across 7MM, and which country will have the largest Bronchiolitis Obliterans Syndrome (BOS) market size during the forecast period (2019–2032)?
- At what CAGR is the Bronchiolitis Obliterans Syndrome (BOS) market expected to grow by 7MM during the forecast period (2019–2032)?
- What would be the Bronchiolitis Obliterans Syndrome (BOS) market outlook across the 7MM forecast period (2019–2032)?
- What would be the Bronchiolitis Obliterans Syndrome (BOS) market growth till 2032, and what will be the resultant market size in 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights
- What are the disease risk, burden, and regional/ethnic differences of Bronchiolitis Obliterans Syndrome (BOS)?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the UK, and Japan?
- What is the historical Bronchiolitis Obliterans Syndrome (BOS) patient pool in seven major markets covering the United States, EU4 and the UK, and Japan?
- What would be the forecasted patient pool of Bronchiolitis Obliterans Syndrome (BOS) in seven major markets covering the United States, EU4 and the UK, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population with Bronchiolitis Obliterans Syndrome (BOS)?
- Out of all 7MM countries, which country would have the highest prevalent population of Bronchiolitis Obliterans Syndrome (BOS) during the forecast period (2019–2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Bronchiolitis Obliterans Syndrome (BOS) treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Bronchiolitis Obliterans Syndrome (BOS) in the US, Europe, and Japan?
- What are the Bronchiolitis Obliterans Syndrome (BOS) marketed drugs and their respective MoA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Bronchiolitis Obliterans Syndrome (BOS)?
- How many therapies are in development by each company for Bronchiolitis Obliterans Syndrome (BOS) treatment?
- How many emerging therapies are in the mid-stage and late stage of development for Bronchiolitis Obliterans Syndrome (BOS) treatment?
- What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to the Bronchiolitis Obliterans Syndrome (BOS) therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies for Bronchiolitis Obliterans Syndrome (BOS) and their status?
- What are the current challenges faced in drug development?
- What key designations have been granted for the emerging therapies for Bronchiolitis Obliterans Syndrome (BOS)?
- What are the global historical and forecasted markets of Bronchiolitis Obliterans Syndrome (BOS)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Bronchiolitis Obliterans Syndrome (BOS) market.
- To understand the future market competition in the Bronchiolitis Obliterans Syndrome (BOS) market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Bronchiolitis Obliterans Syndrome (BOS) in the US, EU4 and the UK, and Japan.
- Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Bronchiolitis Obliterans Syndrome (BOS) market.
- To understand the future market competition in the Bronchiolitis Obliterans Syndrome (BOS) market.
1. Key Insights
2. Report Introduction
3. Bronchiolitis Obliterans Syndrome (BOS) Market Overview at a Glance
3.1. Market Share (%) Distribution of BOS by Drug Class in 2019
3.2. Market Share (%) Distribution of BOS by Drug Class in 2032
4. Executive Summary of Bronchiolitis Obliterans Syndrome (BOS)
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Clinical Manifestations
6.3. Signs and Symptoms
6.4. Causes and Risk factors
6.5. Classification
6.6. Pathogenesis
6.7. Diagnosis
6.7.1. Differential diagnosis
6.7.2. Diagnostic algorithm
6.8. Treatment
6.8.1. Treatment algorithm
6.8.2. Treatment guidelines for the management of BOS
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: The 7MM
7.3. Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM
7.4. Epidemiology Scenario in the United States
7.4.1. Total diagnosed prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the United States
7.4.2. Grade-specific Bronchiolitis Obliterans Syndrome (BOS) cases in the United States
7.4.3. Total treated cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States
7.5. Epidemiology Scenario in EU4 and the UK
7.5.1. Total diagnosed prevalence of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK
7.5.2. Grade-specific Bronchiolitis Obliterans Syndrome (BOS) cases in EU4 and the UK
7.5.3. Total treated cases of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK
7.6. Epidemiology Scenario in Japan
7.6.1. Total diagnosed prevalence of Bronchiolitis Obliterans Syndrome (BOS) in Japan
7.6.2. Grade-specific Bronchiolitis Obliterans Syndrome (BOS) cases in Japan
7.6.3. Total treated cases of Bronchiolitis Obliterans Syndrome (BOS) in Japan
8. Patient Journey
9. Key Endpoints in Bronchiolitis Obliterans Syndrome (BOS) Clinical Trials
10. Emerging Therapies
10.1. Key Competitors
10.2. Liposomal Cyclosporine A: Zambon Pharma
10.2.1. Product description
10.2.2. Other developmental activities
10.2.3. Clinical development
10.3. SERETIDE: GlaxoSmithKline
10.3.1. Product description
10.3.2. Clinical development
10.4. Itacitinib: Incyte Corporation
10.4.1. Product description
10.4.2. Clinical development
10.4.3. Safety and efficacy
10.5. JAKAFI (ruxolitinib): Incyte Corporation
10.5.1. Product description
10.5.2. Clinical development
10.5.3. Safety and efficacy
10.6. MPH966 (alvelestat): Mereo Biopharma
10.6.1. Product description
10.6.2. Other developmental activities
10.6.3. Clinical development
10.6.4. Safety and efficacy
10.7. ESBRIET (pirfenidone): Genentech
10.7.1. Product description
10.7.2. Clinical development
10.7.3. Safety and efficacy
11. Bronchiolitis Obliterans Syndrome: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Outlook
11.3. Attribute Analysis
11.4. Key Market Forecast Assumptions
11.5. Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM
11.6. Market Size in the United States
11.6.1. Total market size of Bronchiolitis Obliterans Syndrome (BOS) in the United States
11.6.2. Market size of Bronchiolitis Obliterans Syndrome (BOS) by therapies in the United States
11.7. Market Size in EU4 and the UK
11.7.1. Total market size of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK
11.7.2. Market size of Bronchiolitis Obliterans Syndrome (BOS) by therapies in EU4 and the UK
11.8. Japan Market Size
11.8.1. Total market size of Bronchiolitis Obliterans Syndrome (BOS) in Japan
11.8.2. Market size by therapies of Bronchiolitis Obliterans Syndrome (BOS) in Japan
12. Market Access and Reimbursement
12.1. Reimbursement
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Appendix
16.1. Bibliography
16.2. Acronyms and Abbreviations
16.3. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
List of Table
Table 1: Summary of Bronchiolitis Obliterans Syndrome (BOS), Market, Epidemiology, and Key Events (2019–2032)
Table 2: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM (2019–2032)
Table 3: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the United States(2019–2032)
Table 4: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) Cases in the United States (2019–2032)
Table 5: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States (2019–2032)
Table 6: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK (2019–2032)
Table 7: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) Cases in EU4 and the UK (2019–2032)
Table 8: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK (2019–2032)
Table 9: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in Japan (2019–2032)
Table 10: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) Cases in Japan (2019–2032)
Table 11: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in Japan (2019–2032)
Table 12: Key Competitors – Emerging Drugs
Table 13: Liposomal Cyclosporine A, Clinical Trial Description, 2023
Table 14: SERETIDE, Clinical Trial Description, 2023
Table 15: Itacitinib, Clinical Trial Description, 2023
Table 16: JAKAFI (ruxolitinib), Clinical Trial Description, 2023
Table 17: Alvelestat, Clinical Trial Description, 2023
Table 18: ESBRIET (pirfenidone), Clinical Trial Description, 2023
Table 19: Key Market Forecast Assumptions for Liposomal Cyclosporine A
Table 20: Key Market Forecast Assumptions for Itacitinib
Table 21: Key Market Forecast Assumptions for JAKAFI
Table 22: Key Market Forecast Assumptions for Alvelestat
Table 23: Market Size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM, in USD million (2019–2032)
Table 24: Market Size of Bronchiolitis Obliterans Syndrome (BOS) in the United States, in USD million (2019–2032)
Table 25: Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in the United States, in USD million (2019–2032)
Table 26: Market Size of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK, in USD million (2019–2032)
Table 27: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in EU4 and the UK, in USD million (2019–2032)
Table 28: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) in Japan, in USD million (2019–2032)
Table 29: Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in Japan, in USD million (2019–2032)
List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Clinical Manifestations of Bronchiolitis Obliterans Syndrome (BOS)
Figure 3: Risk Factors Involved in Bronchiolitis Obliterans Syndrome (BOS)
Figure 4: Pathogenesis of Bronchiolitis Obliterans Syndrome (BOS)
Figure 5: Diagnostic Methods for Bronchiolitis Obliterans Syndrome (BOS)
Figure 6: Differential Diagnosis of Delayed Post-transplant Lung Function Decline
Figure 7: Algorithm for the Diagnosis of Bronchiolitis Obliterans Syndrome (BOS)
Figure 8: Diagnostic and Work-up Algorithm for Bronchiolitis Obliterans Syndrome (BOS)
Figure 9: Treatment Algorithm for Bronchiolitis Obliterans Syndrome (BOS)
Figure 10: Treatment Algorithm for Bronchiolitis Obliterans Syndrome (BOS)
Figure 11: Treatment Algorithm for Bronchiolitis Obliterans Syndrome (BOS)
Figure 12: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM (2019–2032)
Figure 13: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in the United States (2019–2032)
Figure 14: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) Cases in the United States (2019–2032)
Figure 15: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States (2019–2032)
Figure 16: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK (2019–2032)
Figure 17: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) Cases in EU4 and the UK (2019–2032)
Figure 18: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK (2019–2032)
Figure 19: Total Diagnosed Prevalence of Bronchiolitis Obliterans Syndrome (BOS) in Japan (2019–2032)
Figure 20: Grade-specific Bronchiolitis Obliterans Syndrome (BOS) cases in Japan (2019–2032)
Figure 21: Total Treated Cases of Bronchiolitis Obliterans Syndrome (BOS) in Japan (2019–2032)
Figure 22: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM, USD million (2019–2032)
Figure 23: Market Size of Bronchiolitis Obliterans Syndrome (BOS) in the United States, USD million (2019–2032)
Figure 24: Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in the United States, in USD million (2019–2032)
Figure 25: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) in EU4 and the UK, in USD million (2019–2032)
Figure 26: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in EU4 and the UK, in USD million (2019–2032)
Figure 27: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) in Japan, in USD million (2019–2032)
Figure 28: Total Market Size of Bronchiolitis Obliterans Syndrome (BOS) by Therapies in Japan, in USD million (2019–2032)
Zambon Pharma
GlaxoSmithKline
Incyte Corporation
Mereo Biopharma
Genentech